canakinumab

Showing 2 posts of 2 posts found.

novartis_outside_1

Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients

November 6, 2020
Medical Communications, Research and Development COVID-19, Novatis, canakinumab

Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to …

FDA wants more information on Novartis arthritis drug

August 31, 2011
Sales and Marketing FDA, Ilaris, Novarits, canakinumab

The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …

Latest content